Israel Englander’s Oaktree Acquisition Corp III Life Sciences OACC Stock Holding History

Israel Englander’s Portfolio OACC Stock Details OACC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.87M	Hold	175,000	–	–	﹤0.01%	3869
2026 Q1	$1.85M	Sell	175,000 -98,914	-36%	-$1.05M	﹤0.01%	3941
2025 Q4	$2.9M	Hold	273,914	–	–	﹤0.01%	3603
2025 Q3	$2.88M	Hold	273,914	–	–	﹤0.01%	3710
2025 Q2	$2.86M	Sell	273,914 -200,000	-42%	-$2.07M	﹤0.01%	3554
2025 Q1	$4.85M	Buy	+473,914	New	+$4.76M	﹤0.01%	2896

Other funds holding OACC

AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return

FBCM

Fort Baker Capital Management Larkspur, California $1.37B AUM 26.91% 1-Year Est. Return

DAM

Decagon Asset Management London, United Kingdom $525M AUM 50.51% 1-Year Est. Return

ECP

Empyrean Capital Partners Los Angeles, California $3.03B AUM 47.81% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

BGGS

Boussard & Gavaudan Gestion SAS Paris, France $1.99B AUM

Linden Advisors New York $19.3B AUM 1.47% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Sculptor Capital New York $12.3B AUM 40.26% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Israel Englander's OACC Position: Q2 2026 in Review

Israel Englander held its Oaktree Acquisition Corp III Life Sciences (OACC) position steady in Q2 2026 at 175,000 shares worth $1.87M. The position accounts for ﹤0.01% of the portfolio, ranked #3869.

Israel Englander first reported a position in OACC in Q1 2025 and has held it in 6 quarters since. The position peaked at $4.85M in Q1 2025. 50 funds tracked by Wall St. Rank hold OACC as of Q2 2026.

Israel Englander held 175,000 shares of Oaktree Acquisition Corp III Life Sciences worth $1.87M as of Q2 2026.
Israel Englander left its Oaktree Acquisition Corp III Life Sciences share count unchanged in Q2 2026.
Oaktree Acquisition Corp III Life Sciences made up ﹤0.01% of Israel Englander's portfolio in Q2 2026, its #3869 holding.
Israel Englander first reported a position in Oaktree Acquisition Corp III Life Sciences in Q1 2025 and has held it in 6 quarters since.
Israel Englander's Oaktree Acquisition Corp III Life Sciences position peaked at $4.85M in Q1 2025.
50 funds tracked by Wall St. Rank held Oaktree Acquisition Corp III Life Sciences as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.